Major Depressive Disorder Epidemiology Forecast

DelveInsight’s ‘Major Depressive Disorder–Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Major Depressive Disorder Disease Understanding

Depression is a common mental disorder that presents with depressed mood, loss of interest or pleasure in regular activities, decreased energy, feelings of guilt or low self-worth, disturbed sleep or appetite, and poor concentration. Major depressive disorder is the most prevalent and disabling form of depression. In addition to the immediate symptoms of depression, MDD results in poor quality of life overall, decreased productivity, and can increase mortality from suicide.


It is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts. As per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), an individual must have five of the above-mentioned symptoms, of which one must be a depressed mood or anhedonia causing social or occupational impairment, to be diagnosed with MDD.


The treatment of MDD is segmented based on various phases including acute phase, continuation phase, and maintenance phase of treatment. Different types of depression require different treatment. Mild symptoms may be relieved by learning about the condition, lifestyle changes (such as regular physical exercise), and psychological therapy provided by a mental health professional or via online e-therapies. For moderate to more severe depression, Pharmacological treatments are likely to be required, in combination with these other treatments.

Major Depressive Disorder Epidemiology

The Major Depressive Disorder epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Major Depressive Disorder epidemiology segmented as the 12 Months Prevalent cases of Major Depressive Disorder, Gender-specific prevalent case of Major Depressive Disorder, Severity-specific prevalent cases of Major Depressive Disorder and Relapsed/refractory cases of Major Depressive Disorder. The report includes the prevalent scenario of Major Depressive Disorder symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Major Depressive Disorder Epidemiology

The epidemiology segment also provides the Major Depressive Disorder epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total 12-month prevalent population of Major Depressive Disorder Associated in 7MM countries was estimated to be 43,845,330 cases in 2020 and expected to decline at a CAGR of 0.45 % for the study period, i.e., 2018–2030.

  • As per the estimates, the US has the highest Incident population of Major Depressive Disorder
  • Among the EU5 countries, France had the highest Incident population of Major Depressive Disorder. On the other hand, Spain had the lowest number of cases at 2,605,870 cases in 2020.

Scope of the Report

  • Major Depressive Disorder report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Major Depressive Disorder(MDD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Major Depressive Disorder in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Major Depressive Disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Major Depressive Disorder
  • The report provides the segmentation of the Major Depressive Disorder epidemiology by Prevalent Cases of Major Depressive Disorder in 7MM
  • The report provides the segmentation of the Major Depressive Disorder epidemiology by Age-specific Incident Cases of Major Depressive Disorder in 7MM

Report Highlights

  • 10-year Forecast of Major Depressive Disorder epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Major Depressive Disorder
  • Incident Cases according to segmentation: Type-specific Incidence of Major Depressive Disorder, Gender-specific Incidence of Major Depressive Disorder, Treated Cases of Major Depressive Disorder

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Major Depressive Disorder?
  • What are the key findings of Major Depressive Disorder epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018–2030)?
  • What would be the total number of patients with Major Depressive Disorder across the 7MM during the forecast period (2018–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018–2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2018–2030)?
  • What are the disease risk, burden, and unmet needs of Major Depressive Disorder?
  • What are the currently available treatments for Major Depressive Disorder?

Reasons to buy

The Major Depressive Disorder Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Major Depressive Disorder market
  • Quantify patient populations in the global Major Depressive Disorder market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Major Depressive Disorder therapeutics in each of the markets covered
  • Understand the magnitude of Major Depressive Disorder population by its prevalent cases
  • Understand the magnitude of Major Depressive Disorder population by its type and gender-specific cases
  • The Major Depressive Disorder Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Major Depressive Disorder Market Overview at a Glance

3.1. Market Share (%) Distribution of MDD in 2018

3.2. Market Share (%) Distribution of MDD in 2030

4. Executive Summary of Major Depressive Disorder

5. Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Types

5.4. Causes

5.5. Pathophysiology of Depression

5.6. Genetic basis of MDD

5.7. Biomarkers

5.8. Diagnosis and severity

5.8.1. The Diagnostic and Statistical Manual of Mental Disorders (DSM)

5.8.1.1. DSM-IV-TR Criteria for MDD

5.8.1.2. DSM-V: Diagnostic Criteria

5.8.1.3. Differential Diagnosis

5.8.1.4. DSM-IV-TR Criteria for Major Depressive Disorder

5.8.1.5. Depression Rating Scale

5.8.1.6. Montgomery–Åsberg Depression Rating Scale (MADRS)

5.8.1.7. Depression Rating Scale (DRS)

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total 12 months Prevalent Patient Population of Major Depressive Disorder

6.3. The United States

6.3.1. 12 Months Prevalent Cases of Major Depressive Disorder in the US

6.3.2. Gender-specific Prevalence of Major Depressive Disorder in the US

6.3.3. Severity Specific Cases of Major Depressive Disorder in the US

6.3.4. Relapse/Refractory Cases of Major Depressive Disorder in the US

6.4. EU5

6.4.1. Germany

6.4.1.1. 12 Months Prevalent Cases of Major Depressive Disorder in Germany

6.4.1.2. Gender-specific Prevalence of Major Depressive Disorder in Germany

6.4.1.3. Severity Specific Cases of Major Depressive Disorder in Germany

6.4.1.4. Relapse/Refractory Cases of Major Depressive Disorder in Germany

6.4.2. France

6.4.2.1. 12 Months Prevalent Cases of Major Depressive Disorder in France

6.4.2.2. Gender-specific Prevalence of Major Depressive Disorder in France

6.4.2.3. Severity Specific Cases of Major Depressive Disorder in France

6.4.2.4. Relapse/Refractory Cases of Major Depressive Disorder in France

6.4.3. Italy

6.4.3.1. 12 Months Prevalent Cases of Major Depressive Disorder in Italy

6.4.3.2. Gender-specific Prevalence of Major Depressive Disorder in Italy

6.4.3.3. Severity Specific Cases of Major Depressive Disorder in Italy

6.4.3.4. Relapse/Refractory Cases of Major Depressive Disorder in Italy

6.4.4. Spain

6.4.4.1. 12 Months Prevalent Cases of Major Depressive Disorder in Spain

6.4.4.2. Gender-specific Prevalence of Major Depressive Disorder in Spain

6.4.4.3. Severity Specific Cases of Major Depressive Disorder in Spain

6.4.4.4. Relapse/Refractory Cases of Major Depressive Disorder in Spain

6.4.5. United Kingdom

6.4.5.1. 12 Months Prevalent Cases of Major Depressive Disorder in the UK

6.4.5.2. Gender-specific Prevalence of Major Depressive Disorder in the UK

6.4.5.3. Severity Specific Cases of Major Depressive Disorder in the UK

6.4.5.4. Relapse/Refractory Cases of Major Depressive Disorder in the UK

6.5. Japan

6.5.1. 12 Months Prevalent Cases of Major Depressive Disorder in Japan

6.5.2. Gender-specific Prevalence of Major Depressive Disorder in Japan

6.5.3. Severity Specific Cases of Major Depressive Disorder in Japan

6.5.4. Relapse/Refractory Cases of Major Depressive Disorder in Japan

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Table

Table 1: Summary of Major Depressive Disorder, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Assessing the severity of depression

Table 3: DSM-IV-TR diagnostic criteria - MDD

Table 4: DSM-IV-TR diagnostic criteria for MDD, Single episode

Table 5: DSM-IV-TR diagnostic criteria for MDD, Recurrent

Table 6: Selected DSM-IV-TR Major Depressive Episode Specifier

Table 7: Major depressive disorder diagnostic criteria according to DSM-V

Table 8: General Diagnostic Criteria of a Depressive episode according to ICD-10

Table 9: Severity Criteria of a Depressive episode according to ICD-10

Table 10: 12 Months Prevalent Patient Population of MDD in the 7MM (2018–2030)

Table 11: 12 Months Prevalent Cases of Major Depressive Disorder in the US (2018–2030)

Table 12: Gender-specific Prevalence of Major Depressive Disorder in the US (2018–2030)

Table 13: Severity Specific Cases of Major Depressive Disorder in the US (2018–2030)

Table 14: Relapse/Refractory Cases of Major Depressive Disorder in the US (2018–2030)

Table 15: 12 Months Prevalent Cases of Major Depressive Disorder in Germany (2018–2030)

Table 16: Gender-specific Prevalence of Major Depressive Disorder in Germany (2018–2030)

Table 17: Severity Specific Cases of Major Depressive Disorder in Germany (2018–2030)

Table 18: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2018–2030)

Table 19: 12 Months Prevalent Cases of Major Depressive Disorder in France (2018–2030)

Table 20: Gender-specific Prevalence of Major Depressive Disorder in France (2018–2030)

Table 21: Severity Specific Cases of Major Depressive Disorder in France (2018–2030)

Table 22: Relapse/Refractory Cases of Major Depressive Disorder in France (2018–2030)

Table 23: 12 Months Prevalent Cases of Major Depressive Disorder in Italy (2018–2030)

Table 24: Gender-specific Prevalence of Major Depressive Disorder in Italy (2018–2030)

Table 25: Severity Specific Cases of Major Depressive Disorder in Italy (2018–2030)

Table 26: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2018–2030)

Table 27: 12 Months Prevalent Cases of Major Depressive Disorder in Spain (2018–2030)

Table 28: Gender-specific Prevalence of Major Depressive Disorder in Spain (2018–2030)

Table 29: Severity Specific Cases of Major Depressive Disorder in Spain (2018–2030)

Table 30: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2018–2030)

Table 31: 12 Months Prevalent Cases of Major Depressive Disorder in the UK (2018–2030)

Table 32: Gender-specific Prevalence of Major Depressive Disorder in the UK (2018–2030)

Table 33: Severity Specific Cases of Major Depressive Disorder in the UK (2018–2030)

Table 34: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2018–2030)

Table 35: 12 Months Prevalent Cases of Major Depressive Disorder in Japan (2018–2030)

Table 36: Gender-specific Prevalence of Major Depressive Disorder in Japan (2018–2030)

Table 37: Severity Specific Cases of Major Depressive Disorder in Japan (2018–2030)

Table 38: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2018–2030)

List of Figures

Figure 1: Structural and Functional Brain Abnormalities in Patients with Major Depressive Disorder

Figure 2: 12 Months Prevalent Patient Population of MDD in the 7MM (2018–2030)

Figure 3: 12 Months Prevalent Cases of Major Depressive Disorder in the US (2018–2030)

Figure 4: Gender-specific Prevalence of Major Depressive Disorder in the US (2018–2030)

Figure 5: Severity Specific Cases of Major Depressive Disorder in the US (2018–2030)

Figure 6: Relapse/Refractory Cases of Major Depressive Disorder in the US (2018–2030)

Figure 7: 12 Months Prevalent Cases of Major Depressive Disorder in Germany (2018–2030)

Figure 8: Gender-specific Prevalence of Major Depressive Disorder in Germany  (2018–2030)

Figure 9: Severity Specific Cases of Major Depressive Disorder in Germany (2018–2030)

Figure 10: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2018–2030)

Figure 11: 12 Months Prevalent Cases of Major Depressive Disorder in France (2018–2030)

Figure 12: Gender-specific Prevalence of Major Depressive Disorder in France (2018–2030)

Figure 13: Severity Specific Cases of Major Depressive Disorder in France (2018–2030)

Figure 14: Relapse/Refractory Cases of Major Depressive Disorder in France (2018–2030)

Figure 15: 12 Months Prevalent Cases of Major Depressive Disorder in Italy (2018–2030)

Figure 16: Gender-specific Prevalence of Major Depressive Disorder in Italy (2018–2030)

Figure 17: Severity Specific Cases of Major Depressive Disorder in Italy (2018–2030)

Figure 18: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2018–2030)

Figure 19: 12 Months Prevalent Cases of Major Depressive Disorder in Spain (2018–2030)

Figure 20: Gender-specific Prevalence of Major Depressive Disorder in Spain (2018–2030)

Figure 21: Severity Specific Cases of Major Depressive Disorder in Spain (2018–2030)

Figure 22: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2018–2030)

Figure 23: 12 Months Prevalent Cases of Major Depressive Disorder in the UK (2018–2030)

Figure 24: Gender-specific Prevalence of Major Depressive Disorder in the UK (2018–2030)

Figure 25: Severity Specific Cases of Major Depressive Disorder in the UK (2018–2030)

Figure 26: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2018–2030)

Figure 27: 12 Months Prevalent Cases of Major Depressive Disorder in Japan (2018–2030)

Figure 28: Gender-specific Prevalence of Major Depressive Disorder in Japan (2018–2030)

Figure 29: Severity Specific Cases of Major Depressive Disorder in Japan (2018–2030)

Figure 30: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2018–2030)

Figure 31: Basic Principles of Depression Treatment in American and European Guidelines

Figure 32: Seven Major Market Size of Major Depressive Disorder in USD Million (2018–2030)

Figure 33: Market Size of Major Depressive Disorder by Class, USD Million (2018–2030)

Figure 34: The US Market Size of Major Depressive Disorder by Emerging therapies in USD Million

Figure 35: Market Size of Major Depressive Disorder by Class, USD Million (2018–2030)

Figure 36: Germany Market Size of Major Depressive Disorder by Emerging therapies in USD Million

Figure 37: Market Size of Major Depressive Disorder by Class, USD Million (2018–2030)

Figure 38: France Market Size of Major Depressive Disorder by Emerging therapies in USD Million

Figure 39: Market Size of Major Depressive Disorder by Class, USD Million (2018–2030)

Figure 40: Italy Market Size of Major Depressive Disorder by Emerging therapies in USD Million

Figure 41: Market Size of Major Depressive Disorder by Class, USD Million (2018–2030)

Figure 42: The United States Market Size of Major Depressive Disorder by Emerging therapies in USD Million

Figure 43: Market Size of Major Depressive Disorder by Class, USD Million (2018–2030)

Figure 44: The UK Market Size of Major Depressive Disorder by Emerging therapies in USD Million

Figure 45: Market Size of Major Depressive Disorder by Class, USD Million (2018–2030)

Figure 46: Japan Market Size of Major Depressive Disorder by Therapies in USD Million (2018–2030)

  • Tags:
  • Major Depressive Disorder Epidemiol...
  • Major Depressive Disorder
  • Major Depressive Disorder Pipeline
  • Major Depressive Disorder Companie...
  • Major Depressive Disorder prevalen...
  • Major Depressive Disorder incident...
  • Major Depressive Disorder patients...
  • Major Depressive Disorder treatmen...

Forward to Friend

Need A Quote